CLINICAL TRIALS PROFILE FOR MICAFUNGIN SODIUM
✉ Email this page to a colleague
All Clinical Trials for MICAFUNGIN SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01135589 ↗ | Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation | Unknown status | Astellas Pharma Korea, Inc. | Phase 4 | 2010-04-01 | This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure. |
| NCT01135589 ↗ | Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation | Unknown status | Asan Medical Center | Phase 4 | 2010-04-01 | This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure. |
| NCT01344681 ↗ | Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases | Completed | Yonsei University | Phase 2 | 2011-06-01 | This study of chemotherapy occurred during the neutropenic fever in patients with antibiotic refractory fever. The investigators evaluate efficacy and safety of micafungin sodium (mycamine ® Injection) 100mg dose compare to itraconazole (Sporanox ® Injection) 200mg as a control and this study is prospective, randomized, non-inferiority trials. Therefore, this study was planned for review of the safety and efficacy in korean patients. |
| NCT01417169 ↗ | Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation | Unknown status | Seoul National University Hospital | Phase 2 | 2011-08-01 | This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure. |
| NCT02678598 ↗ | A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections | Completed | Astellas Pharma China, Inc. | 2015-03-01 | The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MICAFUNGIN SODIUM
Condition Name
| Condition Name for MICAFUNGIN SODIUM | |
| Intervention | Trials |
| Neutropenia | 2 |
| Hematological Diseases | 1 |
| Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease | 1 |
| Hematopoietic Stem Cell Transplantation | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for MICAFUNGIN SODIUM
Clinical Trial Progress for MICAFUNGIN SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for MICAFUNGIN SODIUM
Sponsor Name
